Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer

Oncologist

Volumn 8, Issue 3, 2003, Pages 232-240

  Verma, Shailendra ^a   Ilersich, A Lane ^b  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Capecitabine; Docetaxel; Metastatic breast cancer; Pharmacoeconomic; Population based

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; DOCETAXEL;

ARTHRALGIA; ARTICLE; BREAST CANCER; CANADA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG EFFICACY; FEVER; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEALTH CARE SYSTEM; HOSPITALIZATION; HUMAN; METASTASIS; MONEY; MONOTHERAPY; MYALGIA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; POPULATION MODEL; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SURVIVAL TIME; UTILIZATION REVIEW;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; BUDGETS; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASM METASTASIS; ONTARIO; PACLITAXEL; POPULATION SURVEILLANCE; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE; WOMEN'S HEALTH;

EID: 0037683726     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.8-3-232     Document Type: Article

References (24)

1. Nabholtz JM, Senn HJ, Bezwoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999;17:1413-1424.
2. Sjöström J, Blomqvist C, Mouridsen H et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999;35:1194-1201.
3. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-2823.
4. Reichardt P, von Minckwitz G, Lück HJ et al. Capecitabine: the new standard in metastatic breast cancer failing anthracycline and taxane-containing chemotherapy? Mature results of a large multicenter phase II trial. Eur J Cancer 2001;37(suppl 6):191.
5. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281.
6. Schüller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45:291-297.
7. Sawada N, Ishikawa T, Fukase Y et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013-1019.
8. Laupacis A, Feeny D, Detsky AS et al. Tentative guidelines for using clinical and economic evaluations revisited. Can Med Assoc J 1993;148:927-929.
9. Will BP, Berthelot JM, Le Petit C et al. Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer 2000;36:724-735.
10. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
11. Smith IE. Efficacy and safety of Hereeptin® in women with metastatic breast cancer: results from pivotal clinical studies. Anticancer Drugs 2001;12(suppl 4):S3-S10.
12. Reaume MN, Coyle D, Quin C et al. Comparative cost-efficiency of platinum based combination chemotherapy regimens for advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001;20:241a.
13. Weinstein MC. Time-preference studies in the health care context. Med Decis Making 1993;13:218-219.
14. Smith TJ, Hillner BE, Neighbors DM et al. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 1995;13:2166-2173.
15. Drummond M, O'Brien B, Stoddardt G et al. Methods for the Economic Evaluation of Health Care Programmes, Second Edition. Oxford: Oxford University Press, 1997:1-316.
16. Earle CC, Chapman RH, Baker CS et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000;18:3302-3317.
17. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998;339:974-984.
18. Nabholtz JM, Gelmon K, Bontenbal M et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-1867.
19. Nabholtz JM, Tonkin K, Smylie M et al. Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer? Expert Opin Pharmacother 2000;1:187-206.
20. Brown RE, Hutton J. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs 1998;9:899-907.
21. Yee GC. Cost-utility analysis of taxane therapy. Am J Health Syst Pharm 1997;54(suppl 2):S11-S15.
22. Hutton J, Brown R, Borowitz M et al. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 1996;9(suppl 2):8-22.
23. Twelves C, Fumoleau P, Jones SE et al. Adding Xeloda® (capecitabine) to docetaxel significantly improves survival and does not compromise quality of life in patients with metastatic breast cancer [abstract 542]. Breast Cancer Res Treat 2001;69:307.
24. O'Shaughnessy JA, Jones SE, Vukelja SJ et al. Pharmaco-economic analysis of Xeloda® (capecitabine) in combination with docetaxel for the treatment of advanced breast cancer pretreated with anthracyclines [abstract 264]. Breast Cancer Res Treat 2001;69:252.